Pazopanib Hydrochloride CAS 635702-64-6 Ịdị Ọcha>99.0% (HPLC) API Foto egosipụtara

Pazopanib Hydrochloride CAS 635702-64-6 Ịdị Ọcha>99.0% (HPLC) Ụlọ ọrụ API

Nkọwa dị mkpirikpi:

Aha kemịkal: Pazopanib Hydrochloride

Nọmba ekwentị: 635702-64-6

Ọdịdị: Ọcha ka ọ dị ntakịrị ntụ ntụ edo edo

Dị ọcha:> 99.0% (HPLC)

Tyrosine kinase receptor inhibitor maka ọgwụgwọ carcinoma renal cell dị elu ma ọ bụ sarcoma anụ ahụ dị nro dị elu

API Ogo dị elu, mmepụta azụmahịa

Inquiry: alvin@ruifuchem.com

Zitere anyị email

Nkọwa ngwaahịa

Ngwaahịa ndị emetụtara

Mkpado ngwaahịa

Nkọwa:

Onye nrụpụta nwere ịdị ọcha dị elu yana ịdị mma kwụsie ike
Aha kemịkal: Pazopanib Hydrochloride
Nọmba ekwentị: 635702-64-6
Tyrosine kinase receptor inhibitor maka ọgwụgwọ ọrịa akwara renal cell carcinoma ma ọ bụ sarcoma anụ ahụ dị nro dị elu bụ ndị natara tupu ọgwụgwọ chemotherapy.
API Ogo dị elu, mmepụta azụmahịa

Njirimara kemịkalụ:

Aha Chemical	Pazopanib Hydrochloride
Ụdị okwu	pazopanib HCl;GW786034 HCl;Votrient;5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl) (methyl) amino] pyrimidin-2-yl] amino]-2-methylbenzenesulfonamide Hydrochloride
Nọmba CAS	635702-64-6
Nọmba CAT	RF-API93
Ọnọdụ Ahịa	Na Akụrụngwa, Mpụta Ihe ruru narị narị kilograms
Usoro ihe omimi	C21H23N7O2S.ClH
Ibu molekụla	473,987
Solubility	DMSO
Ebe Na-agbaze	300.0 ~ 304.0 ℃
Ụdị	Ruifu Chemical

Nkọwapụta:

Ihe	Nkọwapụta
Ọdịdị	Ọcha ka ọ dị ntakịrị ntụ ntụ edo edo
njirimara	Ụdị nnabata infraed nke nlele ule dabara na nke ọkọlọtọ
Ihe fọdụrụ na mgbanye	≤0.50%
Ọdịghị ọcha nke Onye ọ bụla	≤0.30%
Mgbakọta adịghị ọcha	≤1.50%
Ọla dị arọ	≤10ppm
Ụzọ ịdị ọcha / nyocha	≥99.0% (HPLC)
Nlele ọkọlọtọ	Standardkpụrụ ụlọ ọrụ
Ojiji	API, Tyrosine kinase receptor inhibitor

Ngwungwu & Nchekwa:

ngwugwu: Kalama, Aluminom foil bag, kaadiboodu drum, 25kg / Drum, ma ọ bụ dị ka ndị ahịa chọrọ.

Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ọkụ, mmiri mmiri na ụmụ ahụhụ.

Uru:

Ajụjụ:

Ngwa:

Pazopanib Hydrochloride (CAS 635702-64-6) bụ multi-tyrosine kinase inhibitor nke vaskụla endothelial growth factor receptor (VEGFR) -1, VEGFR-2, VEGFR-3, platelet-ewepụtara uto ihe nnabata (PDGFR) -α na - β, fibroblast growth factor receptor (FGFR) -1 na -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T-cell kinase (Itk), protein lymphocyte kpọmkwem tyrosine kinase (Lck), na transmembrane glycoprotein tyrosine. kinase (cFms).Na vitro, pazopanib gbochiri ligand-induced autophosphorylation nke VEGFR-2, Kit, na PDGFR-beta nnabata.Na vivo, pazopanib gbochiri phosphorylation VEGF na-ebute VEGFR-2 n'ime akpa ume òké, angiogenesis na ụdị òké, yana uto nke ụfọdụ tumor xenografts mmadụ na ụmụ oke.Ndị nchịkwa nri na ọgwụ ọjọọ nke US kwadoro ya maka carcinoma renal cell na 2009 ma na-ere ya n'okpuru aha ahia Votrient site n'aka onye na-emepụta ọgwụ, GlaxoSmithKline.Votrient bụ ihe mgbochi kinase egosiri maka ọgwụgwọ ndị ọrịa nwere: 1) carcinoma gbasara akụrụ dị elu.2) sarcoma anụ ahụ dị nro dị elu bụ ndị natara tupu ọgwụgwọ chemotherapy.